ストックスクリーナーアプリを入手
0.0003
50.00%
0.000100
Effector Therapeutics Inc (EFTR) 最新ニュース
Better Therapeutics, Inc. (BTTX) Stock Price, News, Quote & History - Yahoo Finance
Effector Therapeutics Inc (NASDAQ: EFTR) Share Price, EFTR Stock News, EFTR Share Price & Updates - Kalkine
Enterprise value to revenue forward of eFFECTOR Therapeutics Inc – MUN:LWK - TradingView
Competitive Analysis: Leading Companies and New Entrants in - openPR.com
Expanded Access And Rollover Design Help CytoDyn Reach High-Need Cancer Patients - Clinical Leader
Attovia Therapeutics Appoints John W. Smither to Board of Directors - WBOC TV
If You Invested $1,000 in Ampio Pharma (AMPE) - Stock Titan
If You Invested $1,000 in Effector Therapeutics Inc (EFTR) - Stock Titan
If You Invested $1,000 in Innoveren Scientific Inc (IVRN) - Stock Titan
Price to earnings forward of eFFECTOR Therapeutics, Inc. – OTC:EFTR - TradingView
Price to book forward of eFFECTOR Therapeutics Inc – GETTEX:LWK - TradingView
Price to sales forward of eFFECTOR Therapeutics, Inc. – OTC:EFTR - TradingView
Price to sales forward of eFFECTOR Therapeutics Inc – GETTEX:LWK - TradingView
Enterprise value to EBITDA forward of eFFECTOR Therapeutics, Inc. – OTC:EFTR - TradingView
Enterprise value to EBITDA forward of eFFECTOR Therapeutics Inc – GETTEX:LWK - TradingView
eFFECTOR Therapeutics Inc Actuals & Estimates (OTC:EFTR) - TradingView
eFFECTOR Therapeutics Inc Actuals & Estimates (LS:A3ELKJ) - TradingView
PD-1 and PD-L1 Inhibitors Market Business Intelligence and Forecast Report 2026 to 2035 - openPR.com
What Does the Future Hold for Immune Effector Cell Therapies? - CancerNetwork
Calumet, IncCommon Stock (NQ: CLMT - FinancialContent
In vivo reprogramming of cytotoxic effector CD8 T cells via fractalkine-conjugated mRNA-LNPs - Science | AAAS
Bioinorganic Site-Specific Conjugation of Multi-Arm Linkers to Create Pharmaceuticals With Targeting and Effector Functions - Wiley Online Library
Non-covid mRNA Vaccine and Therapeutics Market Supply Chain Analysis and Revenue Forecast 2026 to 2035 - openPR.com
Analysis of Key Market Segments Influencing the RNA Targeting Small Molecules Therapeutics Market - openPR.com
DNA-guided CRISPR–Cas12a effectors for programmable RNA recognition and cleavage - Nature
Insider ownership and executive pay at CERo Therapeutics (NASDAQ: CERO) - Stock Titan
Stock List: Research Stocks from Around the World - GuruFocus
eFFECTOR Therapeutics Inc (EFTRW) - Minichart
IOBTQ Stock Price and Chart — OTC:IOBTQ - TradingView
Entia Biosciences, Inc. (ERGO) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Celularity Inc. (CELU) stock price, news, quote and history - uk.finance.yahoo.com
Novartis to acquire Excellergy for up to $2 billion - National Today
Excellergy to be acquired by Novartis for up to USD 2 - GlobeNewswire
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors - Yahoo Finance
Selective fluorination of Fc glycans enhances antibody-mediated effector functions - PNAS
EFTR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - bioinformant.com
EFTR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CapEx per share of eFFECTOR Therapeutics Inc – MUN:LWK - TradingView
MBX Biosciences (Nasdaq: MBX) adds Burlington lab, names interim CFO - Stock Titan
Reprogramming The Tumor Microenvironment Bringing A Metabolic Checkpoint Therapy Into The Clinic - Clinical Leader
Head-To-Head Comparison: eFFECTOR Therapeutics (NASDAQ:EFTR) & Bio-Path (NASDAQ:BPTH) - Defense World
ZIMCF Stock Price, News & Analysis - Stock Titan
Functional antibody signatures following therapeutic immunization in Simian and Human immunodeficiency virus infection - Nature
Medical Crossfire® From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium - OncLive
Indian American Premal Patel joins Elephas Biosciences as CMO - The American Bazaar
Working (Well) With Patient Advocates: The Sponsor POV - Clinical Leader
ELEPHAS BIOSCIENCES STRENGTHENS SCIENTIFIC AND CLINICAL LEADERSHIP AS COMPANY ADVANCES TOWARD COMMERCIAL AVAILABILITY OF ITS LIVE-TUMOR IMMUNOLOGY PLATFORM - PR Newswire
Reaching Patients Where They Are: Moving CGT Care into the Community - HMP Global Learning Network
FACT's New Standards for Immune Effector Cells in the Community Clinical Setting Help Bring Cell Therapies Closer to Patients - Yahoo Finance
cells from effector T cells for cell therapy of inflammatory diseases - Science | AAAS
Excellergy Debuts with $70 Million Series A Financing to - GlobeNewswire
Robot End-Effector Market Is Expected To Reach US$13.76 Billion By 2031 With CAGR Of 14.5% | The Insight Partners - Yahoo Finance
High binding potency overcomes the requirement of Fc effector functions for broadly reactive anti-alphavirus antibodies - Science | AAAS
VantAI, Halda Therapeutics Launch $1B+ Proximity-Based Therapy Collaboration - Genetic Engineering and Biotechnology News
Transferrin receptor–targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA - Science | AAAS
Spatial Organisation of Tumour cDC1 States Correlates with Effector and Stem‐Like CD8+ T Cells Location - Wiley Online Library
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):